Flagship explainer
What drives ENDONOVO THERAPEUTICS, INC.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$18.5M | FY2022 |
| |
| Income before tax | −$18.5M | FY2022 |
|
| Operating income | −$3.3M | FY2022 |
|
| $135355 | FY2022 |
| |
| Ending assets | $1.3M | FY2022 |
|
| Beginning assets | $2M | FY2021 |
|
| −$32.2M | FY2022 |
| |
| −$15.8M | FY2021 |
|
Source:
- SEC filingFiling detailsAccession 0001493152-22-009861
- SEC filingFiling detailsAccession 0001493152-23-012553